is a mycosis that affects the skin and subcutaneous tissues. The etiologic agent is a black yeast that belongs to the Chaetothyriales order and Herpotrichiellaceae family. This fungus lives in the soil and plants of tropical and subtropical countries. In Brazil, the main etiologic agent is Fonsecaea pedrosoi, additionally infections with Exophiala jeanselmei and Exophiala spinifera have been documented. 1 The infection occurs after a contact of the lesioned skin with black yeast.Classical treatment of CBM is performed with itraconazole (200-400 mg/day), that can be associated with terbinafine (250 mg/day). These drugs are administrated for a long period of time, that basically depends on the individual response of the patient. Despite the long course of treatment, some patients do not show improvement of lesions and others exhibit signs of drug intolerance. Physical approaches, such as surgery, cryotherapy, and thermotherapy, 2 can be employed in the treatment; however, the efficacy is limited. On the other side, untreated patients display a progressive growth of the lesions, compromising the affected member. Moreover, patients presenting lesions lasting over years may develop skin carcinomas. Therefore, it is urgent to create new strategies to treat this neglected fungal disease.An interesting approach to treat infectious diseases is to combine drugs; thus, an elevated cure rate has been recorded when immunomodulatory agents were combined with drugs classically used in therapy. 3 Imiquimod, an antitumor agent, is able to stimulate the immune system through the activation of Toll-like receptors, 4 improving the immune response against infectious agents. 5,6 In fact, it has been demonstrated that patients with CBM over a